Preparation of endostatin-loaded chitosan nanoparticles and evaluation of the antitumor effect of such nanoparticles on the Lewis lung cancer model.
The purpose of this study was to prepare ES-loaded chitosan nanoparticles (ES-NPs) and evaluate the antitumor effect of these particles on the Lewis lung cancer model. ES-NPs were prepared by a simple ionic cross-linking method. The characterization of the ES-NPs, including size distribution, zeta potential, loading efficiency and encapsulation efficiency (EE), was performed. An in vitro release test was also used to determine the release behavior of the ES-NPs. Cell viability and cell migration were assayed to detect the in vitro antiangiogenic effect of ES-NPs. In order to clarify the antitumor effect of ES-NPs in vivo, the Lewis lung cancer model was used. ES-NPs were successfully synthesized and shown to have a suitable size distribution and high EE. The nanoparticles were spherical and homogeneous in shape and exhibited an ideal releasing profile in vitro. Moreover, ES-NPs significantly inhibited the proliferation and migration of human umbilical vascular endothelial cells (HUVECs). The in vivo antiangiogenic activity was evaluated by ELISA and immunohistochemistry analyses, which revealed that ES-NPs had a stronger antiangiogenic effect for reinforced anticancer activity. Indeed, even the treatment cycle in which ES-NPs were injected every seven days, showed stronger antitumor effect than the free ES injected for 14 consecutive days. Our study confirmed that the CS nanoparticle is a feasible carrier for endostatin to be used in the treatment of lung cancer.
a Department of Oncology , The Affiliated Hospital of Southwest Medical University , Luzhou , P.R. China.
Rui-Lin
RL
Ding
a Department of Oncology , The Affiliated Hospital of Southwest Medical University , Luzhou , P.R. China.
Fang
F
Xie
a Department of Oncology , The Affiliated Hospital of Southwest Medical University , Luzhou , P.R. China.
Yue
Y
Hu
a Department of Oncology , The Affiliated Hospital of Southwest Medical University , Luzhou , P.R. China.
Shao-Zhi
SZ
Fu
a Department of Oncology , The Affiliated Hospital of Southwest Medical University , Luzhou , P.R. China.
Jing-Bo
JB
Wu
a Department of Oncology , The Affiliated Hospital of Southwest Medical University , Luzhou , P.R. China.
Juan
J
Fan
a Department of Oncology , The Affiliated Hospital of Southwest Medical University , Luzhou , P.R. China.
Wen-Feng
WF
He
a Department of Oncology , The Affiliated Hospital of Southwest Medical University , Luzhou , P.R. China.
Yu
Y
He
a Department of Oncology , The Affiliated Hospital of Southwest Medical University , Luzhou , P.R. China.
Ling-Lin
LL
Yang
a Department of Oncology , The Affiliated Hospital of Southwest Medical University , Luzhou , P.R. China.
Sheng
S
Lin
a Department of Oncology , The Affiliated Hospital of Southwest Medical University , Luzhou , P.R. China.
Qing-Lian
QL
Wen
D000818:Animals; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy* / Q000473:pathology; D002465:Cell Movement / Q000187:drug effects / Q000502:physiology; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D048271:Chitosan / Q000008:administration & dosage* / Q000737:chemistry; D004337:Drug Carriers / Q000008:administration & dosage* / Q000737:chemistry; D004353:Drug Evaluation, Preclinical / Q000379:methods; D043169:Endostatins / Q000008:administration & dosage* / Q000737:chemistry; D005260:Female; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D011897:Random Allocation
D004337:Drug Carriers; D043169:Endostatins; D048271:Chitosan
Endostatin; chitosan; drug carrier; lung cancer; nanoparticles